Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelley, D. E.
Right arrow Articles by Goodpaster, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelley, D. E.
Right arrow Articles by Goodpaster, B. H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 24:933-941, 2001
© 2001 by the American Diabetes Association, Inc.

Reviews/Commentaries/Position Statements
Review Article

Skeletal Muscle Triglyceride

An aspect of regional adiposity and insulin resistance

David E. Kelley, MD1,2 and Bret H. Goodpaster, PHD1

1 Department of Medicine, University of Pittsburgh School of Medicine
2 Department of Veterans Affairs, Pittsburgh, Pennsylvania

ABSTRACT

Recent evidence derived from four independent methods indicates that an excess triglyceride storage within skeletal muscle is linked to insulin resistance. Potential mechanisms for this association include apparent defects in fatty acid metabolism that are centered at the mitochondria in obesity and in type 2 diabetes. Specifically, defects in the pathways for fatty acid oxidation during postabsorptive conditions are prominent, leading to diminished use of fatty acids and increased esterification and storage of lipid within skeletal muscle. These impairments in fatty acid metabolism during fasting conditions may be related to a metabolic inflexibility in insulin resistance that is not limited to defects in glucose metabolism during insulin-stimulated conditions. Thus, there is substantial evidence implicating perturbations in fatty acid metabolism during accumulation of skeletal muscle triglyceride and in the pathogenesis of insulin resistance. Weight loss by caloric restriction improves insulin sensitivity, but the effects on fatty acid metabolism are less conspicuous. Nevertheless, weight loss decreases the content of triglyceride within skeletal muscle, perhaps contributing to the improvement in insulin action with weight loss. Alterations in skeletal muscle substrate metabolism provide insight into the link between skeletal muscle triglyceride accumulation and insulin resistance, and they may lead to more appropriate therapies to improve glucose and fatty acid metabolism in obesity and in type 2 diabetes.

Abbreviations: CPT, carnitine palmitoyl transferase • CT, computed tomography • FABP, fatty acid–binding protein • FFA, free fatty acid • leg RQ, respiratory quotient across the leg • MRS, magnetic resonance spectroscopy • UCP2, uncoupling protein 2

Nearly all individuals with type 2 diabetes are markedly insulin resistant, and the majority of them are obese. This review examines mechanisms that might contribute to the association between insulin resistance and obesity, emphasizing 1), established and newer concepts of regional adipose tissue distribution, and 2), triglyceride content within skeletal muscle. Physiological and cellular mechanisms that lead to an excess accumulation of lipids within skeletal muscle will also be examined. The hypothesis that is addressed in this review is that tissue accumulation of triglyceride makes a major contribution to skeletal muscle insulin resistance and occurs due to reduced reliance on free fatty acid oxidation during postabsorptive conditions.

Abdominal Adipose Tissue Distribution and Insulin Resistance
Obesity, even if not complicated by diabetes, is associated with insulin-resistant glucose metabolism in skeletal muscle. Considerable insight into the link between obesity and insulin resistance has been gained from studies of adipose tissue distribution. Omental and mesenteric adipose tissue, so-called visceral adiposity, is recognized as a depot strongly associated with insulin resistance of skeletal muscle (1), as well as with dyslipidemia (2) and increased risks for hypertension and glucose intolerance (1,3,4). For example, Banerji et al. (5) observed that variance in visceral adiposity accounted for much of the inter-individual variation in insulin resistance among a cohort of African-American individuals with type 2 diabetes, some of whom manifested an "insulin-sensitive" subtype of type 2 diabetes. In a recent weight-loss intervention trial, our laboratory found that among nondiabetic obese subjects, the decrease in visceral adiposity was the body composition change that best predicted the improvement in insulin sensitivity after weight loss (6). However, emerging findings suggest that other aspects of regional adiposity also contribute to the link between obesity and insulin resistance.

In type 2 diabetes, there is an increased prevalence of hepatosteatosis (increased lipid accumulation in the liver) that appears to be related to adiposity, particularly visceral adiposity. A recent clinical investigation in insulin-treated patients with type 2 diabetes indicates that hepatic triglyceride content is a strong determinant of hepatic insulin resistance (789). Fatty acid flux to the liver may be a determinant of rates of hepatic glucose production (10). Patterns of hepatic fatty acid metabolism and hepatocyte triglyceride concentrations are potentially important areas warranting additional investigation so that there may be better understanding of the relationship between regional lipid distribution and insulin resistance in obesity and type 2 diabetes.

Lower-Extremity Adipose Tissue and Insulin Resistance
There is considerable adipose tissue in the lower extremities; however, subcutaneous adipose tissue in the legs is generally regarded as a relatively weak marker of insulin resistance (11). In a recent study from our laboratories, Goodpaster et al. (12) used cross-sectional computed tomography (CT) imaging to measure the quantity and distribution of adipose tissue in the thigh. The investigators followed the novel body composition approach of using anatomic criteria to subdivide adipose tissue planes into adipose tissue present above the fascia lata (termed subcutaneous adipose tissue) and adipose tissue present below the fascia lata (termed subfascial adipose tissue). Their findings confirm the prior perception that subcutaneous adiposity of the legs—although it is greatly increased in obesity and comprises >90% of thigh adipose tissue, even in lean individuals—is not correlated with rates of insulin-stimulated glucose metabolism. However, several novel observations were made concerning adipose tissue contained beneath muscle fascia. Variance in the amount of adipose tissue beneath muscle fascia correlated with insulin resistance (Fig. 1). Moreover, adipose tissue dispersed within muscle and identifiable by CT imaging as distinct from muscle itself also was strongly correlated to insulin resistance. Interestingly, the quantities of these fat depots contained beneath the fascia and within muscle tissue were substantially smaller than the amount of adipose tissue located subcutaneously, comprising ~10% of leg adipose tissue. These observations suggest that in the lower extremities, the location of adiposity is a key determinant of the link between insulin resistance and obesity. Conceptually, this is analogous to regional distribution of abdominal adipose tissue and its relation to insulin resistance.



View larger version (26K):
[in this window]
[in a new window]
  		Figure 1 — Associations of adipose tissue located beneath the fascia lata in the mid-thigh among lean glucose-tolerant (GT) subjects, obese GT subjects, and obese subjects with type 2 diabetes (n = 68).

 
Skeletal Muscle Triglyceride and Insulin Resistance
In the study of adipose tissue distribution in the thigh conducted by Goodpaster et al. (12), it was also observed that there was an altered composition of skeletal muscle in obese patients with type 2 diabetes. Skeletal muscle composition, as assessed by CT imaging and expressed on the basis of the distribution of CT attenuation values of muscle, differed in obese patients with type 2 diabetes compared with the skeletal muscle of lean volunteers, as shown in Fig. 2. Attenuation values are the units of measure used in CT imaging to denote tissue density and are referenced to the properties of water to attenuate the transmission of radiation. These findings confirm results from previous studies in which muscle attenuation values were lower in obese patients, particularly those with type 2 diabetes (13,14). Recent studies using chemical phantoms (surrogate "limbs" of known lipid concentration) and tissue biochemical studies (using muscle biopsy samples) confirm that increased lipids are a key determinant of reduced attenuation characteristics of skeletal muscle (15). These findings are of interest because of the potential metabolic implications of altered muscle composition.



View larger version (26K):
[in this window]
[in a new window]
  		Figure 2 — Histograms of the distribution and frequency of pixels across the range of adipose skeletal muscle (0–100 HU) in a representative lean (A) and obese (B) subject. Open bars represent the frequency of pixels from 0 to 29 HU as "low-density muscle" (i.e., >=2 SDs below the mean attenuation value for normal lean skeletal muscle); filled bars represent the frequency of pixels from 30 to 100 HU as "normal-density muscle." In the obese individual, more skeletal muscle is represented as low-density muscle. Adapted from Diabetes 48:839–847, 1999.

 
Reduced muscle attenuation has been found to correlate significantly with insulin resistance, even after adjusting for the amount of visceral adiposity or overall obesity (13). Indeed, among a cohort of 40 nondiabetic individuals with a BMI >30 kg/m2, muscle attenuation was the strongest body composition correlate of insulin resistance. Additionally, muscle attenuation has been found to correlate negatively with aerobic fitness (13) and with the oxidative enzyme capacity of skeletal muscle (16).

Another elegant approach recently developed to investigate the metabolic significance of muscle lipid content is magnetic resonance spectroscopy (MRS). Aside from the noninvasive nature of MRS, an advantage of this approach appears to be the capability of MRS to distinguish the signal attributable to protons of the lipids contained within muscle fibers from those located outside the muscle fibers (17). Subsequent validation studies demonstrated that proton MRS of muscle in animals and humans can be used to observe intracellular lipid (18). Perseghin et al. (19) used this method to report that lipids contained within muscle fibers were strongly correlated with the severity of insulin resistance. Moreover, it was observed that this depot was increased among first-degree relatives of type 2 diabetic individuals and was related to the expression of insulin resistance in this high-risk group (19).

The link between insulin resistance and triglyceride content measured in human muscle biopsy samples has also been established. Pan et al. (20) determined the triglyceride content in vastus lateralis muscle among 38 nondiabetic Pima Indian men, an ethnic group with a pronounced disposition for obesity and type 2 diabetes. Insulin sensitivity, measured using the hyperinsulinemic-euglycemic clamp technique, was inversely related to skeletal muscle triglyceride content, as shown in Fig. 3. Moreover, the relation between insulin resistance and muscle triglyceride was independent of total adiposity. In animal studies, it was previously observed that a high-fat diet induced insulin resistance in skeletal muscle and that this was related to the fat content of muscle (21). Accordingly, selective muscle triglyceride depletion by leptin administration reversed insulin resistance in animals (22).



View larger version (28K):
[in this window]
[in a new window]
  		Figure 3 — Relationship between skeletal muscle triglyceride content and insulin sensitivity. Adapted from Diabetes 46:983–988, 1997.

 
Another approach to directly examine lipid content in muscle fibers is histochemical staining, which provides visual information on the distribution of lipids within myocytes. Phillips et al. (23) used a neutral lipid stain and semiquantitative histological scoring to assess intramuscular lipid in percutaneous biopsy samples from vastus lateralis obtained from 27 nondiabetic women. Neutral lipid staining in skeletal muscle correlated with reduced insulin activation of the enzyme glycogen synthase, a marker enzyme for insulin action and one regarded as rate limiting for glucose storage. Using a more quantitative imaging approach to histological sections of vastus lateralis muscle stained by Oil red O, Goodpaster et al. (24) found that the triglyceride content of myocytes was especially increased in obese patients with type 2 diabetes. Thus, in summary, four distinct methods have been used to support the finding that triglyceride content is increased in skeletal muscle in obesity and type 2 diabetes and is correlated with insulin resistance.

One caution in the interpretation of these data is that an increased muscle triglyceride content is not invariably linked to insulin resistance. Exercise training has been reported to increase muscle triglyceride content (25,26), and chronic exercise increases insulin sensitivity (27,28) as well as the capacity for fatty acid oxidation (29). Studies of exercise physiology indicate that skeletal muscle triglyceride can contribute substantially to the mixture of substrates oxidized by exercising skeletal muscle (303132). Moreover, type 1 skeletal muscle fibers, which manifest increased oxidative enzyme capacity and may have increased insulin sensitivity, increased capacity for fatty acid uptake, and increased triglyceride stores (33). These findings should not be interpreted as contradictory to the findings cited above regarding the link between muscle triglyceride and insulin resistance in obese patients with type 2 diabetes. Rather, the data point to the importance of relating muscle triglyceride content with its capacity for fatty acid metabolism. Muscle triglyceride may not have adverse metabolic consequences in muscle that has the capacity for efficient lipid utilization. Perhaps an excess level of muscle triglyceride merely represents a surrogate for other lipid metabolites in muscle, such as fatty acyl CoA, which are known to confer insulin resistance (34). It is also conceivable that periodic depletion and repletion of muscle triglyceride, as might occur with regular exercise, is not associated with insulin resistance. The inability or failure to periodically deplete triglyceride in muscle, as likely occurs in sedentary individuals, however, is associated with insulin resistance.

Interaction Between Glucose and Fatty Acid Metabolism in Type 2 Diabetes
Plasma fatty acids are an important substrate for skeletal muscle in healthy individuals, as has been recognized for many years, based on the now-classic human physiology studies of Andres et al. (35), and their importance was reconfirmed in more recent clinical investigations (363738). During postabsorptive conditions, such as those that occur after an overnight fast, skeletal muscle has a high fractional extraction of plasma fatty acids, and lipid oxidation accounts for the majority of energy production. It has been postulated that uptake of fatty acids into skeletal muscle may be a saturable process regulated by fatty acid–binding proteins (FABPs) (39). Thus, in addition to its important role as a site for insulin-stimulated glucose utilization, skeletal muscle has a key role in systemic fatty acid utilization, which manifests especially during fasting conditions.

The capacity of skeletal muscle to utilize either lipid or carbohydrate fuels, as well as the potential for substrate competition between fatty acids and glucose, has maintained the interest of investigators of insulin resistance (37,38,40–45). A potential implication of the glucose–fatty acid cycle, which was originally postulated by Randle et al. (46), is that increased lipid availability could interfere with muscle-glucose metabolism and contribute to insulin resistance of obese patients with type 2 diabetes. Studies by several investigators support the concept of impaired insulin-stimulated glucose metabolism by elevated free fatty acids (FFAs) (40,43,45,47). Recent investigations have begun to delineate postreceptor signaling mechanisms that might contribute to fatty acid–induced insulin resistance, with several studies reporting an impact on signaling via the protein kinase C pathway (4849505152), a component of the insulin signaling pathways that has an impact on insulin-stimulated glucose transport.

A collateral concept has emerged, however; it purports that substrate competition might not only operate in the direction of lipid-inducing, insulin-resistant glucose metabolism, but that provision of glucose inhibits oxidation of lipids. Evidence supporting this notion has arisen from studies by Kelley and Mandarino (53) of patients with type 2 diabetes under conditions of fasting hyperglycemia. By using the limb-balance technique, they found that the respiratory quotient across the leg (leg RQ) was elevated (0.92) in type 2 diabetes, denoting increased glucose oxidation and a greatly reduced reliance on fatty acid oxidation. Subsequent reduction of glycemia by a low-dose insulin infusion designed to suppress hepatic glucose output in patients with type 2 diabetes led to a reduction in leg glucose oxidation and increased leg fat oxidation. In lean healthy volunteers, hyperglycemic clamp studies performed while suppressing insulin to basal conditions also caused a rise in leg RQ similar to that found in patients with type 2 diabetes (54). These effects of hyperglycemia were accentuated in obese patients (55). Kelley et al. (43) and Kelley and Simoneau (44) found that skeletal muscle uptake of fatty acids was reduced in obese patients with type 2 diabetes (53) during fasting hyperglycemia, with lower fractional extraction across the leg. More recently, Sidossis et al. (38) confirmed these findings by implicating inhibition of the entry of fatty acids into the mitochondria as the mechanism by which insulin and hyperglycemia inhibit the oxidation of lipids. Cortez et al. (56) and Torgan et al. (57) found increased glucose oxidation in the skeletal muscle of obese insulin-resistant rats. These studies suggest that hyperglycemia perturbs the normal fasting reliance on fatty acid oxidation within skeletal muscle, a finding with potential implications for the pathogenesis of lipid accumulation within skeletal muscle and for obesity in general.

Patients with type 2 diabetes have reduced efficiency in the uptake of plasma FFAs by skeletal muscle (36,44,53). This result has been found using limb-balance methods (44,58) and, more recently, using positron emission tomography imaging in lower-extremity muscle of individuals with impaired glucose tolerance (59). However, reduced fractional extraction of plasma FFAs does not appear to be the sole mechanism that limits fat oxidation. This finding suggests that factors intrinsic to muscle may contribute to decreased fatty acid oxidation and increased storage of fat within muscle.

Mechanisms of Skeletal Muscle Triglyceride Accumulation in Type 2 Diabetes
Plasma concentrations of FFAs play an important role in determining the rate of FFA uptake by skeletal muscle (60). Nonetheless, plasma FFA availability is not the sole factor determining FFA uptake into tissues. One potential site for the regulation of fatty acid metabolism in muscle is fatty acid transport. Multiple proteins have been identified as putative transporters of fatty acids in muscle (60), namely FABP, fatty acid translocase, and fatty acid transport protein, but their role in the regulation of fat metabolism is unclear. In studies of human skeletal muscle, neither the content of cytosolic FABP nor that of the sarcolemmal FABP was diminished in obese subjects with obesity (61). However, Blaak et al. (62) reported reduced FABP in the muscle of diabetic individuals. Further investigation may reveal unidentified mechanisms by which these transport proteins contribute to increased skeletal muscle triglyceride storage in obese patients with type 2 diabetes.

During resting postabsorptive conditions, ~30% of fatty acid flux in the plasma pool is accounted for by oxidation, with the remaining 70% of flux recycled into triglyceride, indicating a physiological reserve that exceeds immediate tissue needs for oxidative substrates. The equilibrium between oxidation and reesterification within muscle is paramount in determining fatty acid storage within tissue. After transport in the sarcoplasm by FABP, and before oxidation, long-chain fatty acids must be activated to long-chain acyl CoA, then translocated into mitochondria by the enzyme complex, carnitine palmitoyl transferase (CPT) I and II. Activity of CPT I is regarded as a key step in the regulation of fatty acid oxidation within muscle (63). The muscle isoform of CPT I is highly sensitive to allosteric inhibition by malonyl CoA, the precursor of fatty acid synthesis (63). Insulin and glucose increase skeletal muscle content of malonyl CoA, suggesting that insulin and glucose inhibit lipid oxidation (64). In animal models of insulin resistance, Ruderman et al. (34) found increased skeletal muscle content of malonyl CoA during postabsorptive conditions, which was consistent with the inhibition of fatty acid oxidation. Simoneau et al. (61) found reduced CPT activity in skeletal muscle of insulin-resistant obese volunteers, who also exhibited reduced rates of fat oxidation across the leg (37). This reduced CPT activity was proportional to an overall reduction in activities of citrate synthase, cytochrome C oxidase, and hydroxyacyl dehydrogenase; enzymes of the tricarboxylic acid cycle; electron transport; and ß-oxidation, respectively (61). Moreover, reduced oxidative enzyme activity has been associated with insulin resistance and with the presence of type 2 diabetes (656667). Thus, the reduction in CPT activity may reflect reduced mitochondrial content, resulting in a reduced capacity for lipid oxidation. Additional evidence pertinent to mitochondrial metabolism in skeletal muscle is the finding of increased content of uncoupling protein 2 (UCP2) in obese patients, and an association between lower rates of fatty acid oxidation across the leg with UCP2 content (68). Taken as a whole, the biochemistry of skeletal muscle in obese patients with type 2 diabetes suggests impairments centered at the mitochondria that direct fatty acids in skeletal muscle toward esterification and storage rather than oxidation.

Impaired Fatty Acid Utilization in Insulin Resistance: Metabolic Inflexibility
Healthy skeletal muscle has substantial metabolic flexibility (69) and switches from predominantly lipid oxidation during fasting conditions, accompanied by high rates of fatty acid uptake (35), to increased glucose uptake, oxidation, and storage under insulin-stimulated conditions with suppression of lipid oxidation (58). Insulin resistance is defined as a reduced insulin stimulation of glucose metabolism. Another aspect of insulin resistance appears to be an inability to suppress lipolysis and lipid oxidation. Obese individuals and those with type 2 diabetes manifest higher lipid oxidation during insulin-stimulated conditions (41), despite lower rates of lipid oxidation during fasting conditions. These findings are actually commensurate with each other, considering that a key metabolic feature of skeletal muscle is its capacity to switch between fuels. This capacity may be lost in insulin resistance.

The concept of metabolic inflexibility in insulin resistance has been demonstrated in recent studies using limb-balance methods to examine rates of substrate uptake and oxidation (37). As shown in Fig. 4, obese subjects had lower fasting rates of lipid oxidation, yet during insulin infusions, rates of lipid oxidation by muscle were higher than in lean subjects. Clearly, lean subjects demonstrated the ability to shift from a reliance on lipid oxidation during fasting to glucose oxidation during insulin infusions. In contrast, obese subjects lacked the capacity to modulate substrate selection during either condition, demonstrating metabolic inflexibility. Lipid oxidation does not increase in all conditions; rather, it is part of an inflexible response to either insulin or fasting in the modulation of substrate oxidation. The diminished capacity of obese individuals to augment lipid oxidation during fasting conditions also predicts the severity of insulin resistance. Thus, lower rates of fatty acid oxidation during fasting are likely a key mechanism leading to excess lipid accumulation within skeletal muscle, which in turn contributes to insulin-resistant glucose metabolism through processes of substrate competition and other mechanisms (70).



View larger version (18K):
[in this window]
[in a new window]
  		Figure 4 — Contributions of lipid and glucose oxidation to resting energy expenditure of the leg. Obese subjects derived relatively less energy from lipid oxidation during basal conditions (*P < 0.01). Lean subjects have greater suppression of lipid oxidation during insulin-stimulated conditions (**P < 0.01). Adapted from Am J Physiol 277:E1130–E1141, 1999.

 
On the basis of these findings, we propose that the mechanisms for an excess lipid accumulation within myocytes in obesity and in type 2 diabetes are related to defects in fatty acid oxidation. We posit that reduced fatty acid oxidation, rather than an increased fatty acid uptake, mediates lipid accumulation. The biochemical mechanism responsible for lower fatty acid oxidation may be diminished entry of acyl CoA into mitochondria secondary to a reduced CPT activity and potentially due to increased malonyl CoA concentrations.

Effect of Weight Loss on Skeletal Muscle Lipid Metabolism
Weight loss can be a highly effective treatment for overweight patients with type 2 diabetes and other cardiovascular risk factors, and indeed it is advocated as the first line of therapy. Weight loss may also play a role in the prevention of type 2 diabetes (71,72). In overweight patients with type 2 diabetes, weight loss can reduce hepatic glucose production (73,74), insulin resistance (73747576), and fasting hyperinsulinemia (747576), and it can improve glycemic control (73747576). Weight loss in type 2 diabetes is also associated with a reduction in blood pressure and an improvement in the lipid profile (77). These benefits can occur with as little as 5–10% weight loss (74,78,79). Moreover, preventing obesity in primates with long-term caloric restriction mitigates the development of insulin resistance (80).

Less is known concerning the effects of weight loss on the pattern of muscle fatty acid metabolism and the accumulation of lipid within muscle. Thus, it is important to consider whether impairments within the pathways of fatty acid utilization in skeletal muscle are primary defects in obese individuals or arise secondarily, after an individual has become obese. This issue is difficult to effectively address by cross-sectional comparisons of lean and obese subjects. One prospective clinical study indicated that lower rates of lipid oxidation were a predisposing factor for greater weight gain (81), and collateral studies revealed that skeletal muscle enzyme activities were implicated in impaired lipid oxidation (82,83). A reduced reliance on lipid oxidation has also been identified as a risk factor for weight regain after weight loss (84). These data raise the possibility that a potential impairment in the capacity for lipid oxidation might be a primary defect in obesity. Weight loss can markedly improve insulin-resistant glucose metabolism in skeletal muscle. When patient response indicates a substantial acquired or secondary component of obesity-related insulin-resistant glucose metabolism, it is important to address whether weight loss can modulate patterns of skeletal muscle metabolism of fatty acids, including the content of fat within muscle.

Goodpaster et al. (6,24), Kelley et al. (37), and Simoneau et al. (61) have addressed the impact of weight loss within a group of obese men and women, for whom the pre–weight loss patterns of muscle fatty acid metabolism have previously been described in this review. The weight-loss intervention decreased weight (by a mean value of ~14 kg), BMI, total fat mass, and subcutaneous and visceral abdominal adipose tissue, and it improved insulin sensitivity. Weight loss also modified the composition of muscle determined from its attenuation characteristics on CT; skeletal muscle attenuation values were increased in a direction indicative of partial reduction in muscle lipid content (6). Furthermore, the cross-sectional area of thigh muscle decreased, which was entirely due to the decrease in the area of low-density muscle, because the area of normal-density muscle did not change (12). Weight loss significantly decreased the amount of neutral lipid contained within muscle fibers (i.e., intramuscular triglycerides) in nondiabetic obese subjects and in obese patients with type 2 diabetes (24). Clearly, clinical weight-loss interventions can reduce excess lipid stored within skeletal muscle, which may mitigate insulin resistance.

The impact of weight loss on muscle fatty acid metabolism was also recently examined by Kelley et al. (37). Although insulin-stimulated glucose metabolism in skeletal muscle was improved by ~50%, the effects of weight loss on fatty acid metabolism were considerably more blunted. The reduced reliance on lipid oxidation during postabsorptive conditions in obese patients persisted after weight loss (Fig. 5). Although rates of FFA uptake across the leg were lower after weight loss during postabsorptive conditions, rates of lipid oxidation across leg tissues continued to be lower after weight loss, resulting in a lower net storage of fatty acids within the leg. Consistent with these findings, activity of CPT did not change, whereas the oxidative enzyme capacity actually decreased after weight loss.



View larger version (17K):
[in this window]
[in a new window]
  		Figure 5 — During fasting conditions, the proportion of energy derived from lipid oxidation was not changed with weight loss (WL), whereas during insulin-stimulated conditions, weight loss resulted in a greater suppression of lipid oxidation (*P < 0.01). Adapted from Am J Physiol 277:E1130–E1141, 1999.

 
Weight loss, however, does seem to influence patterns of muscle fatty acid metabolism during insulin-stimulated conditions. During insulin infusions, arterial FFA levels and rates of uptake for plasma FFAs across the leg were lower after weight loss than during the same conditions before weight loss. Insulin infusions also significantly suppressed fat oxidation by leg tissues, compared with the markedly blunted response to insulin before weight loss. This finding indicates more effective insulin suppression of lipolysis in leg tissues after weight loss, a pattern similar to that observed in lean subjects. Taken together with previous reports (848586), these data indicate that after weight loss, there is a persistent impairment of fasting patterns of fatty acid metabolism by skeletal muscle but improved insulin suppression of both lipolysis and lipid oxidation. Exercise training in lean healthy individuals increases the oxidative enzyme capacity and rates of fatty acid oxidation from intramuscular stores during exercise conditions (87). This finding suggests that impaired lipid metabolism and an increased muscle triglyceride content could be primary impairments leading to obesity, rather than merely resulting from obesity. Perhaps exercise, either alone or in combination with weight loss, can effectively improve skeletal fatty acid metabolism concomitant with improving insulin-resistant glucose metabolism.

SUMMARY

Nearly 40 years ago, Randle et al. (46) published a series of experiments that revealed that fatty acids could inhibit the utilization of glucose in skeletal muscle. Their seminal work has stimulated an ongoing interest in the hypothesis that substrate competition is a potential mechanism that contributes to insulin resistance in individuals with obesity and type 2 diabetes. Their hypothesis has been substantiated, although not without important modifications. It remains clear that fatty acids can impair glucose metabolism during insulin-stimulated conditions. However, investigators over the past 10 years, both in clinical and in animal models of type 2 diabetes and obesity, have observed that skeletal muscle in these disorders can also manifest a decreased reliance on fat oxidation during fasting conditions. To some extent, impairment of the postabsorptive fat oxidation in muscle may result from glucose inhibition of fatty acid utilization—a "reverse" Randle cycle. However, biochemical examinations of skeletal muscle, as well as physiological investigations, also indicate that insulin-resistant skeletal muscle in individuals with obesity and type 2 diabetes has a reduced capacity for fat oxidation and a tendency toward increased lipid storage. Thus, the concept of insulin resistance includes impairments in fatty acid oxidation and denotes a distinct metabolic inflexibility with regard to substrate selection. These aspects of altered substrate metabolism in skeletal muscle offer new insights into the strong link between obesity and insulin resistance. These findings also pose a therapeutic challenge: How can we rectify not only glucose metabolism, but also skeletal muscle–fatty acid metabolism in obese patients with type 2 diabetes?

FOOTNOTES

Address correspondence and reprint requests to David E. Kelley, MD, University of Pittsburgh School of Medicine, Department of Medicine, Division of Endocrinology and Metabolism, E1140 Biomedical Science Tower, 200 Lothrop St., Pittsburgh, PA 15261.

Received for publication 12 September 2000 and accepted in revised form 12 January 2001.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

References

  1. Despres JP: Abdominal obesity as important component of insulin-resistance syndrome (Review). Nutrition 9:452–459, 1993[Medline]
  2. Tchernof A, Lamarche B, Prud’Homme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Despres JP: The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19:629–637, 1996[Abstract]
  3. Björntorp P: Metabolic implications of body fat distribution. Diabetes Care 14:1132–1143, 1991[Abstract]
  4. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S: Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54–59, 1987[Medline]
  5. Banerji M, Chaiken R, Gordon D, Lebowitz H: Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes 44:141–146, 1995[Abstract]
  6. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL: Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 48:839–847, 1999[Abstract]
  7. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol 84:1513–1517, 1999[Abstract/Free Full Text]
  8. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107:450–455, 1999[Medline]
  9. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749–758, 2000[Abstract]
  10. Rebrin K, Steil GM, Getty L, Bergman RN: Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 44:1038–1045, 1995[Abstract]
  11. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ: Abdominal fat and insulin resistance in normal and overweight women. Diabetes 45:633–638, 1996[Abstract]
  12. Goodpaster BH, Thaete FL, Kelley DE: Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 71:885–892, 2000[Abstract/Free Full Text]
  13. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE: Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46:1579–1585, 1997[Abstract]
  14. Kelley DE, Slasky S, Janosky J: Skeletal muscle density: effects of obesity and non-insulin-dependent diabetes mellitus. Am J Clin Nutr 54:509–515, 1991[Abstract/Free Full Text]
  15. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R: Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 89:104–110, 2000[Abstract/Free Full Text]
  16. Simoneau JA, Colberg SR, Thaete FL, Kelley DE: Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. FASEB J 9:273–278, 1995[Abstract]
  17. Boesch C, Slotboom J, Hoppeler H, Kreis R: In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn Reson Med 37:484–493, 1997[Medline]
  18. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, Stein DT: Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 276:E977–E989, 1999[Abstract/Free Full Text]
  19. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L: Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H–13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48:1600–1606, 1999[Abstract]
  20. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB, Storlein LH: Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46:983–988, 1997[Abstract]
  21. Storlien L, Jenkins A, Chisholm D, Pascoe W, Khouri S, Kraegen EW: Influence of dietary fat composition on development of insulin resistance in rats: relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes 40:280–289, 1991[Abstract]
  22. Shimabukuro M, Koyama K, Chen G, Wang MY, Trieu F, Lee Y, Newgard CB, Unger RH: Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A 94:4637–4641, 1997[Abstract/Free Full Text]
  23. Phillips DI, Caddy S, Ilic V, Fielding BA, Frayn KN, Borthwick AC, Taylor R: Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 45:947–950, 1996[Medline]
  24. Goodpaster BH, Theriault R, Watkins SC, Kelley DE: Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism 49:467–472, 2000[Medline]
  25. Hoppeler H, Howald H, Conley K, Lindstedt SL, Claassen H, Vock P, Weibel ER: Endurance training in humans: aerobic capacity and structure of skeletal muscle. J Appl Physiol 59:320–327, 1985[Abstract/Free Full Text]
  26. Morgan TE, Short FA, Cobb LA: Effect of long-term exercise on skeletal muscle lipid composition. J Appl Physiol 216:82–86, 1969
  27. Dela F, Larsen JJ, Mikines KJ, Ploug T, Petersen LN, Galbo H: Insulin-stimulated muscle glucose clearance in patients with NIDDM. Diabetes 44:1010–1020, 1995[Abstract]
  28. Mayer-Davis EJ, D’Agostino R Jr, Karter AJ, Haffner SM, Rewers MJ, Saad M, Bergman RN: Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. JAMA 279:669–674, 1998[Abstract/Free Full Text]
  29. Gollnick PD, Saltin B: Significance of skeletal muscle oxidative enzyme enhancement with endurance training. Clin Physiol 2:1–12, 1982[Medline]
  30. Carlson LA, Ekelund LG, Fröberg SO: Concentration of triglycerides, phospholipids and glycogen in skeletal muscle and of free fatty acids and ß-hydroxybutyric acid in blood in man in response to exercise. Eur J Clin Invest 1:248–254, 1971[Medline]
  31. Fröberg SO, Mossfeldt F: Effect of prolonged strenuous exercise on the concentration of triglycerides, phospholipids and glycogen in muscle of man. Acta Physiol Scand 82:167–171, 1971[Medline]
  32. Romijn JA, Coyle EF, Sidossis LS, Gastaldelli A, Horowitz JF, Endert E, Wolfe RR: Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. Am J Physiol 265:E380–E391, 1993[Abstract/Free Full Text]
  33. Dyck DJ, Peters SJ, Glatz J, Gorski J, Keizer H, Kiens B, Liu S, Richter EA, Spriet LL, van der Vusse GJ, Bonen A: Functional differences in lipid metabolism in resting skeletal muscle of various fiber types. Am J Physiol 271:E340–E351, 1997
  34. Ruderman NB, Saha AK, Vavvas D, Kurowski T, Laybutt DR, Schmitz-Peiffer C, Biden T, Kraegen EW: Malonyl CoA as a metabolic switch and a regulator of insulin sensitivity. In Skeletal Muscle Metabolism in Exercise and Diabetes. Richter EA, Kiens B, Galbo H, Eds. New York, Plenum Press, 1998, p. 263–270
  35. Andres R, Cadar G, Zierler K: The quantitatively minor role of carbohydrate in oxidative metabolism by skeletal muscle in intact man in the basal state. J Clin Invest 35:671–682, 1956
  36. Colberg S, Simoneau JA, Thaete FL, Kelley DE: Impaired FFA utilization by skeletal muscle in women with visceral obesity. J Clin Invest 95:1846–1853, 1995
  37. Kelley DE, Goodpaster BH, Wing RR, Simoneau JA: Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity and weight loss. Am J Physiol 277:E1130–E1141, 1999[Abstract/Free Full Text]
  38. Sidossis LS, Stuart CA, Shulman GI, Lopaschuk GD, Wolfe RR: Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria. J Clin Invest 98:2244–2250, 1996[Medline]
  39. Berk PD, Zhou S-L, Bradbury M, Stump D, Han N-I: Characterization of membrane transport processes: lessons learned from the study of BSP, bilirubin, and fatty acid uptake. Semin Liver Dis 16:107–120, 1996[Medline]
  40. Boden G, Chen X, Ruiz J, White JV, Rossetti L: Mechanisms of fatty acid–induced inhibition of glucose uptake. J Clin Invest 93:2438–2446, 1994
  41. Felber JP, Ferrannini E, Golay A, Meyer H, Thiebauld D, Curchod B, Maeder E, Jequier E, DeFronzo R: Role of lipid oxidation in the pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 36:1341–1350, 1987[Abstract]
  42. Groop LC, Saloranta C, Shank M, Bonnadonna RC, Ferrannini E, DeFronzo RA: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 72:96–107, 1991[Abstract]
  43. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ: Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest 92:93–98, 1993
  44. Kelley DE, Simoneau JA: Impaired FFA utilization by skeletal muscle in NIDDM. J Clin Invest 94:2349–2356, 1994
  45. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI: Mechanism of free fatty acid–induced insulin resistance in humans. J Clin Invest 97:2859–2865, 1996[Medline]
  46. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785–789, 1963[Medline]
  47. Boden G, Chen X: Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 96:1261–1268, 1995
  48. Cortright RN, Azevedo JL Jr, Zhou Q, Sinha M, Pories WJ, Itani SI, Dohm GL: Protein kinase C modulates insulin action in human skeletal muscle. Am J Physiol 278:E553–E662, 2000[Abstract/Free Full Text]
  49. Itani SI, Zhou Q, Pories WJ, MacDonald KG, Dohm GL: Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes 49:1353–1358, 2000[Abstract]
  50. Laybutt DR, Schmitz-Peiffer S, Ruderman NB, Chisholm D, Biden T, Kraegen EW: Activation of protein kinase C 101 {therefore}{phi} {therefore}{varsigma} 12 may contribute to muscle insulin resistance induced by lipid accumulation during chronic glucose infusion in rats (Abstract). Diabetes 46:241A, 1997
  51. Schmitz-Peiffer C, Oakes ND, Browne CL, Kraegen EW, Biden TJ: Alterations in the expression and cellular localization of protein kinase C isozymes {epsilon} and {theta} are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 46:169–178, 1997[Abstract]
  52. Schmitz-Peiffer C, Oakes ND, Browne CL, Kraegen EW, Biden TJ: Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653. Am J Physiol 273:E915–E921, 1997[Abstract/Free Full Text]
  53. Kelley DE, Mandarino LJ: Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus. J Clin Invest 86:1999–2007, 1990
  54. Mandarino LJ, Consoli A, Kelley DE: Differential regulation of intracellular glucose metabolism by glucose and insulin in human muscle. Am J Physiol 265:E898–E905, 1996
  55. Mandarino LJ, Consoli A, Kelley DE: Effects of obesity and NIDDM on glucose and insulin regulation of substrate oxidation in skeletal muscle. Am J Physiol 270: E463–E470, 1996
  56. Cortez MY, Torgan CE, Brozinick JT, Miller RH, Ivy JL: Effects of pyruvate and dihydroxyacetone consumption on the growth and metabolic state of obese Zucker rats. Am J Clin Nutr 53:847–853, 1991[Abstract/Free Full Text]
  57. Torgan CE, Brozinick JT, Willems MET, Ivy JL: Substrate utilization during acute exercise in obese Zucker rats. J Appl Physiol 69:1987–1991, 1990[Abstract/Free Full Text]
  58. Kelley D, Reilly J, Veneman T, Mandarino LJ: Effect of insulin on skeletal muscle glucose storage, oxidation, and glycolysis in humans. Am J Physiol 258:E923–E929, 1990[Abstract/Free Full Text]
  59. Kelley DE, Mintun MA, Watkins SC, Simoneau JA, Jadali F, Fredrickson A, Beattie J, Theriault R: The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 97:2705–2713, 1996[Medline]
  60. Turcotte LP: Fatty acid binding proteins and muscle lipid metabolism in skeletal muscle. In Biochemistry of Exercise. Hargreaves M, Ed. Champaign, IL, Human Kinetics, 1999, p. 210–215
  61. Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE: Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J 13:2051–2060, 1999[Abstract/Free Full Text]
  62. Blaak EE, Wagenmakers AJM, Glatz JFC, Wolffenbuttel BHR, Kemerink GJ, Langenberg CJM, Heidendal GAK, Saris WHM: Plasma FFA utilization and fatty acid–binding protein content are diminished in type 2 diabetic muscle. Am J Physiol 279:146–154, 2000
  63. McGarry JD, Brown NF: The mitochondrial carnitine palmitoyltransferase system: from concept to molecular analysis. Eur J Biochem 224:1–14, 1997[Medline]
  64. Saha AK, Vavvas T, Kurowski TG, Apazidis A, Witters LA, Shafrir E, Ruderman NB: Malonyl-CoA regulation in skeletal muscle: its link to cell citrate and the glucose-fatty acid cycle. Am J Physiol 272:E641–E648, 1997[Abstract/Free Full Text]
  65. Kruszynska YE, Mulford MI, Baloga J, Yu JG, Olefsky JM: Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47:1107–1113, 1998[Abstract]
  66. Pendergrass M, Koval J, Vogt C, Yki-Jarvinen H, Iozzo P, Pipek R, Ardehali H, Printz R, Granner DK, DeFronzo RA, Mandarino LJ: Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 47:387–394, 1998[Abstract]
  67. Simoneau JA, Kelley DE: Altered skeletal muscle glycolytic and oxidative capacities contribute to insulin resistance in NIDDM. J Appl Physiol 83:166–171, 1997[Abstract/Free Full Text]
  68. Simoneau JA, Kelley DE, Neverova M, Warden CH: Overexpression of muscle uncoupling protein-2 content in human obesity associates with reduced skeletal muscle lipid utilization. FASEB J 12:1739–1745, 1998[Abstract/Free Full Text]
  69. Saltin B, Gollnick PD: Skeletal muscle adaptability: significance for metabolism and performance. In Handbook of Physiology. Section 10: Skeletal Muscle. Peachey LD, Adrian R, Geiger SR, Eds. Baltimore, Williams & Wilkins, 1983, p. 555–632
  70. Kelley DE, Mandarino LJ: Fuel selection in human skeletal muscle in insulin resistance. Diabetes 49:677–683, 2000[Abstract]
  71. Long SD, O’Brien K, MacDonald KG Jr, Leggett-Frazier N, Swanson MS, Pories WJ, Caro JF: Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes: a longitudinal interventional study. Diabetes Care 17:372–375, 1994[Abstract]
  72. Wing RR, Vendetti E, Jakicic JM, Polley BA, Lang W: Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 21:350–359, 1998[Abstract]
  73. Henry RR, Wallace P, Olefsky JM: Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 35:990–998, 1986[Abstract]
  74. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M: Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 77:1287–1293, 1993[Abstract]
  75. Wing RR, Blair E, Marcus M, Epstein LH, Harvey J: Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 97:354–362, 1994[Medline]
  76. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN: Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 17:30–36, 1994[Abstract]
  77. Maggio CA, Pi-Sunyer FX: The prevention and treatment of obesity: application to type 2 diabetes (Review). Diabetes Care 20:1744–1766, 1997[Medline]
  78. Goldstein DJ: Beneficial effects of modest weight loss. Int J Obes 16:397–415, 1992[Medline]
  79. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D: Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 147:1749–1753, 1987[Abstract]
  80. Bodkin NL, Ortmeyer HK, Hansen BC: Long-term dietary restriction in older-aged rhesus monkeys: effects on insulin resistance. J Gerontol A Biol Sci Med Sci :B142–B147, 1995
  81. Zurlo F, Lillioja S, Esposito-DelPuente A, Nyomba BL, Raz I, Saad MF, Swiunburn WC, Knowler WC, Bogardus C, Ravussin E: Low ratio of fat to carbohydrate oxidation as a predictor of weight gain: a study of 24-h RQ. Am J Physiol 259:E650–E657, 1990[Abstract/Free Full Text]
  82. Ferraro R, Eckel R, Larson E, Fontvielle A, Rising R, Jensen D, Ravussin E: Relationship between lipoprotein lipase activity and 24-hour macronutrient oxidation. J Clin Invest 92:441–445, 1993
  83. Zurlo F, Nemeth PM, Choksi RM, Sesodia S, Ravussin E: Whole-body energy metabolism and skeletal muscle biochemical characteristics. Metabolism 43:481–486, 1994[Medline]
  84. Bryson JM, King SE, Burns CM, Baur LA, Swaraj S, Caterson ID: Changes in glucose and lipid metabolism following weight loss produced by a very low calorie diet in obese subjects. Int J Obes 20:338–345, 1996
  85. Blaak EE, Van Baak MA, Kemerink GJ, Pakbiers MT, Heidendal GA, Saris WH: Beta-adrenergic stimulation of skeletal muscle metabolism in relation to weight reduction in obese men. Am J Physiol 267:E316–E322, 1994[Abstract/Free Full Text]
  86. Ranneries C, Bulow J, Buemann B, Christensen NJ, Madsen J, Astrup A: Fat metabolism in formerly obese women. Am J Physiol 274:E155–E161, 1998[Abstract/Free Full Text]
  87. Hurley BF, Nemeth PM, Martin WH, Hagberg JM, Dalsky GP, Holloszy JO: Muscle triglyceride utilization during exercise: effect of training. J Appl Physiol 60:562–567, 1986[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G. Aslanidi, V. Kroutov, G. Philipsberg, K. Lamb, M. Campbell-Thompson, G. A. Walter, S. Kurenov, J. Ignacio Aguirre, P. Keller, K. Hankenson, et al.
Ectopic expression of Wnt10b decreases adiposity and improves glucose homeostasis in obese rats
Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E726 - E736.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G. P. Holloway, A. B. Thrush, G. J. F. Heigenhauser, N. N. Tandon, D. J. Dyck, A. Bonen, and L. L. Spriet
Skeletal muscle mitochondrial FAT/CD36 content and palmitate oxidation are not decreased in obese women
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1782 - E1789.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
W. Guo, T. Pirtskhalava, T. Tchkonia, W. Xie, T. Thomou, J. Han, T. Wang, S. Wong, A. Cartwright, F. G. Hegardt, et al.
Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity
Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1041 - E1051.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. A. Tarnopolsky, C. D. Rennie, H. A. Robertshaw, S. N. Fedak-Tarnopolsky, M. C. Devries, and M. J. Hamadeh
Influence of endurance exercise training and sex on intramyocellular lipid and mitochondrial ultrastructure, substrate use, and mitochondrial enzyme activity
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2007; 292(3): R1271 - R1278.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. Sahlin, M. Mogensen, M. Bagger, M. Fernstrom, and P. K. Pedersen
The potential for mitochondrial fat oxidation in human skeletal muscle influences whole body fat oxidation during low-intensity exercise
Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E223 - E230.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. J. Schilder and J. H. Marden
Metabolic syndrome and obesity in an insect
PNAS, December 5, 2006; 103(49): 18805 - 18809.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
Z. Guo, L. Zhou, and M. D. Jensen
Acute hyperinsulinemia inhibits intramyocellular triglyceride synthesis in high-fat-fed obese rats
J. Lipid Res., December 1, 2006; 47(12): 2640 - 2646.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
G. Mazzali, V. Di Francesco, E. Zoico, F. Fantin, G. Zamboni, C. Benati, V. Bambara, M. Negri, O. Bosello, and M. Zamboni
Interrelations between fat distribution, muscle lipid content, adipocytokines, and insulin resistance: effect of moderate weight loss in older women.
Am. J. Clinical Nutrition, November 1, 2006; 84(5): 1193 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
K. Fosgerau, C. Fledelius, K. E Pedersen, J. B Kristensen, J. R Daugaard, M. A Iglesias, E. W Kraegen, and S. M Furler
Oral administration of glucose promotes intracellular partitioning of fatty acid toward storage in white but not in red muscle.
J. Endocrinol., September 1, 2006; 190(3): 651 - 658.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Lopez-Soriano, C. Chiellini, M. Maffei, P. A. Grimaldi, and J. M. Argiles
Roles of Skeletal Muscle and Peroxisome Proliferator-Activated Receptors in the Development and Treatment of Obesity
Endocr. Rev., May 1, 2006; 27(3): 318 - 329.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
M. Damon, I. Louveau, L. Lefaucheur, B. Lebret, A. Vincent, P. Leroy, M. P. Sanchez, P. Herpin, and F. Gondret
Number of intramuscular adipocytes and fatty acid binding protein-4 content are significant indicators of intramuscular fat level in crossbred Large White x Duroc pigs
J Anim Sci, May 1, 2006; 84(5): 1083 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Qvisth, E. Hagstrom-Toft, S. Enoksson, E. Moberg, P. Arner, and J. Bolinder
Human Skeletal Muscle Lipolysis Is More Responsive to Epinephrine Than to Norepinephrine Stimulation in Vivo
J. Clin. Endoc